Liver Physicians Pioneering National Digital Health Strategy with GE Healthcare
GE Healthcare and Perspectum Diagnostics invest to develop scalable AI solutions to diagnose liver disease with MRI through a newly formed consortium in collab…
6 Nov 2018
LiverMultiScan receives regulatory clearance in Singapore
Oxford University spin-out, Perspectum Diagnostics’ proprietary multiparametric software, LiverMultiScan, aids clinicians in the diagnosis of liver disorders…
1 Oct 2018
NASH-FX trial shows excellent reproducibility of cT1 as a non-invasive biomarker of liver health
Oxford, United Kingdom, September 10th, 2018 | New data published in PLOS One, demonstrate the utility and variability of three non-invasive liver health bioma…
10 Sep 2018
LiverMultiScan receives regulatory clearance for clinical use in Australia
We are delighted to announce today that our flagship product, LiverMultiScan™, has received clearance as a Medical Device from the Therapeutic Goods Administ…
14 Aug 2018
Large population imaging study reveals utility of LiverMultiScan’s cT1 measure
[Oxford, UK], [July 27, 2018] An MRI-based measure, corrected T1 (cT1), could be used as a potential biomarker for liver health, a study in collaboration with …
27 Jul 2018
New paper released from the University of Nottingham on quantitative T1 mapping in liver disease
Recent work from Christopher Bradley and colleagues at Nottingham University demonstrates the feasibility of a quantitative T1 biomarker to accurately evaluate…
10 Jul 2018
Good diagnostic accuracy with non-invasive Multiparametric MRI across a range of liver disease severity
Research led by two leading tertiary UK liver centres, Queen Elizabeth Hospital Birmingham and Royal Infirmary of Edinburgh, showed that multiparametric MRI pe…
10 Jul 2018
Biotech Investors Should Consider The Four Horsemen
"One of the keys to long-term biotech investing is finding the big winners and riding them to huge gains, writes Medical Technology Stock Letter editor John Mc…
6 Jul 2018
Multiparametric liver MRI could refine the way we currently approach testing of therapeutic candidates in preclinical models
Research led by Professor Jonathan Fallowfield, Chair of Translational Liver Research at University of Edinburgh, in collaboration with GlaxoSmithKline, showed…
3 Jul 2018
Analysis of Biobank data shows 1 in 8 adults may have NASH
UK Biobank is a major national and international health resource, and a registered charity in its own right. UK Biobank's aim is to improve the prevention, dia…
15 Apr 2018
LiverMultiScan™ analysis of UK Biobank indicates as many as 1 in 8 adults may have non-alcoholic steatohepatitis (NASH)
Perspectum Diagnostics today revealed new data which indicates that the prevalence of non-alcoholic steatohepatitis (NASH) among UK adults could be as high as …
13 Apr 2018
LiverMultiScan™ Receives FDA 510(k) Clearance for Version 2 of Medical Device
We are delighted to announce that LiverMultiScan™ has received FDA 510(k) clearance for the next release of the software. Read the full press release below: …
27 Nov 2017